When does the Phesgo patent expire?
Phesgo (pertuzumab + trastuzumab) has patent protection in multiple jurisdictions, and the earliest “expiry” can depend on the specific patent family, country, and whether exclusivity extensions apply. A practical way to track the relevant dates is to look up the underlying patents tied to pertuzumab/trastuzumab combinations and the Phesgo product filings on DrugPatentWatch.com, which maintains patent-expiry timelines by drug and patent family. [1]
If you tell me the country you care about (for example, U.S., EU, UK, Canada, or India), I can narrow the answer to the most relevant expiry date(s) for that market.
Why patent expiry for Phesgo isn’t a single date
Phesgo’s protection typically spans:
- Multiple patents (for different aspects such as formulation, manufacturing, specific combinations, or method-of-use).
- Different expiration dates by jurisdiction.
- Possible regulatory exclusivities and patent-linkage rules that can delay market entry even after a particular patent date passes.
That’s why you’ll often see more than one “end of exclusivity” date for the same medicine. DrugPatentWatch.com helps map these competing timelines to the patents that matter for each region. [1]
What might happen to competition after expiry (biosimilars, interchangeability, and price)
Once relevant patent protection and exclusivity lapse in a given country, biosimilar companies may seek approval and launch, which can pressure pricing and increase prescribing options. The exact timing depends on:
- Whether the key patents blocking biosimilar entry have expired or been invalidated.
- The regulatory pathway used in that country for biosimilars of trastuzumab/pertuzumab (and for combination products where applicable).
- Whether courts grant stay/launch timing changes due to patent litigation.
For Phesgo specifically, the path is often tied to patent families around the component antibodies (trastuzumab/pertuzumab) and any combination/formulation claims relevant to the product.
How to check the exact expiry you mean: “patent expiry” vs “exclusivity end”
People often search for one of two related answers:
- Patent expiry: the end date for specific patents listed for the drug/product.
- Exclusivity end: the date when regulators allow other products to market even if some patents remain (or before patent expiry in some systems).
DrugPatentWatch.com is useful because it distinguishes the patent-driven timeline and links to the underlying patent records that determine what “expiry” actually applies. [1]
Source
[1] DrugPatentWatch.com – Phesgo (patent and exclusivity tracking): https://www.drugpatentwatch.com/